Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 379

1.

MiR-433 and miR-22 dysregulations induce HDAC6 overexpression and ciliary loss in cholangiocarcinoma.

Mansini AP, Lorenzo Pisarello MJ, Thelen KM, Cruz-Reyes M, Peixoto E, Jin S, Howard BN, Trussoni CE, Gajdos GB, LaRusso NF, Perugorria MJ, Banales JM, Gradilone SA.

Hepatology. 2018 Feb 6. doi: 10.1002/hep.29832. [Epub ahead of print]

PMID:
29406621
2.

The combination of an HDAC6 inhibitor and a somatostatin receptor agonist synergistically reduces hepato-renal cystogenesis in an animal model of polycystic liver disease.

Lorenzo Pisarello M, Masyuk TV, Gradilone SA, Masyuk AI, Ding JF, Lee PY, LaRusso NF.

Am J Pathol. 2018 Jan 20. pii: S0002-9440(17)30796-4. doi: 10.1016/j.ajpath.2017.12.016. [Epub ahead of print]

PMID:
29366679
3.

Cholangiocytes in health and disease: From basic science to novel treatments.

Banales JM, Marzioni M, LaRusso NF, Jansen P.

Biochim Biophys Acta. 2018 Jan 26. pii: S0925-4439(18)30015-2. doi: 10.1016/j.bbadis.2018.01.014. [Epub ahead of print] No abstract available.

PMID:
29357291
4.

Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.

Murillo Perez F, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group.

Hepatology. 2017 Dec 8. doi: 10.1002/hep.29717. [Epub ahead of print]

PMID:
29220537
5.

Polycystic Liver Disease: The interplay of genes causative for hepatic and renal cystogenesis.

Masyuk TV, Masyuk AI, LaRusso NF.

Hepatology. 2017 Dec 6. doi: 10.1002/hep.29708. [Epub ahead of print] No abstract available.

PMID:
29211938
6.

Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.

Masyuk AI, Masyuk TV, Lorenzo Pisarello MJ, Ding JF, Loarca L, Huang BQ, LaRusso NF.

Hepatology. 2017 Oct 10. doi: 10.1002/hep.29577. [Epub ahead of print]

PMID:
29023824
7.

MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.

Erice O, Munoz-Garrido P, Vaquero J, Perugorria MJ, Fernandez-Barrena MG, Saez E, Santos-Laso A, Arbelaiz A, Jimenez-Agüero R, Fernandez-Irigoyen J, Santamaria E, Torrano V, Carracedo A, Ananthanarayanan M, Marzioni M, Prieto J, Beuers U, Oude Elferink RP, LaRusso NF, Bujanda L, Marin JJG, Banales JM.

Hepatology. 2017 Sep 18. doi: 10.1002/hep.29533. [Epub ahead of print]

PMID:
28922472
8.

A 59-Year-Old Man with New Jaundice.

Mouchli MA, Kurtin PJ, LaRusso NF.

Gastroenterology. 2017 Sep 9. pii: S0016-5085(17)36139-5. doi: 10.1053/j.gastro.2017.09.003. [Epub ahead of print] No abstract available.

PMID:
28899720
9.

Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis.

Loarca L, De Assuncao TM, Jalan-Sakrikar N, Bronk S, Krishnan A, Huang B, Morton L, Trussoni C, Bonilla LM, Krueger E, O'Hara S, Splinter P, Shi G, Pisarello MJL, Gores GJ, Huebert RC, LaRusso NF.

Lab Invest. 2017 Nov;97(11):1385-1396. doi: 10.1038/labinvest.2017.63. Epub 2017 Sep 11.

PMID:
28892096
10.

Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice.

Moncsek A, Al-Suraih MS, Trussoni CE, O'Hara SP, Splinter PL, Zuber C, Patsenker E, Valli PV, Fingas CD, Weber A, Zhu Y, Tchkonia T, Kirkland JL, Gores GJ, Müllhaupt B, LaRusso NF, Mertens JC.

Hepatology. 2018 Jan;67(1):247-259. doi: 10.1002/hep.29464. Epub 2017 Nov 29.

PMID:
28802066
11.

Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?

O'Hara SP, Karlsen TH, LaRusso NF.

Gut. 2017 Nov;66(11):1873-1877. doi: 10.1136/gutjnl-2017-314249. Epub 2017 Jul 21. No abstract available.

12.

Pathobiology of biliary epithelia.

Cheung AC, Lorenzo Pisarello MJ, LaRusso NF.

Biochim Biophys Acta. 2017 Jul 15. pii: S0925-4439(17)30221-1. doi: 10.1016/j.bbadis.2017.06.024. [Epub ahead of print] Review.

PMID:
28716705
13.

Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Cheung AC, LaRusso NF, Gores GJ, Lazaridis KN.

Semin Liver Dis. 2017 May;37(2):159-174. doi: 10.1055/s-0037-1603324. Epub 2017 May 31. No abstract available.

14.

TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.

Masyuk TV, Masyuk AI, Lorenzo Pisarello M, Howard BN, Huang BQ, Lee PY, Fung X, Sergienko E, Ardecky RJ, Chung TDY, Pinkerton AB, LaRusso NF.

Hepatology. 2017 Oct;66(4):1197-1218. doi: 10.1002/hep.29284. Epub 2017 Aug 26.

PMID:
28543567
15.

Doublecortin domain containing protein 2 (DCDC2) genetic variants in primary sclerosing cholangitis.

Cheung AC, Juran BD, Moore RM, LaRusso NF, Lazaridis KN.

J Hepatol. 2017 Sep;67(3):651-652. doi: 10.1016/j.jhep.2017.02.036. Epub 2017 Apr 29. No abstract available.

16.

B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.

Holditch SJ, Schreiber CA, Harris PC, LaRusso NF, Ramirez-Alvarado M, Cataliotti A, Torres VE, Ikeda Y.

Kidney Int. 2017 Sep;92(3):657-668. doi: 10.1016/j.kint.2017.02.017. Epub 2017 Apr 14.

PMID:
28416225
17.

Emerging pharmacologic therapies for primary sclerosing cholangitis.

Cheung AC, Lazaridis KN, LaRusso NF, Gores GJ.

Curr Opin Gastroenterol. 2017 May;33(3):149-157. doi: 10.1097/MOG.0000000000000352. Review.

PMID:
28257308
18.

Role of the Intestinal Microbiome in Cholestatic Liver Disease.

LaRusso NF, Tabibian JH, O'Hara SP.

Dig Dis. 2017;35(3):166-168. doi: 10.1159/000450906. Epub 2017 Mar 1. Review.

PMID:
28249266
19.

ETS Proto-oncogene 1 Transcriptionally Up-regulates the Cholangiocyte Senescence-associated Protein Cyclin-dependent Kinase Inhibitor 2A.

O'Hara SP, Splinter PL, Trussoni CE, Pisarello MJ, Loarca L, Splinter NS, Schutte BF, LaRusso NF.

J Biol Chem. 2017 Mar 24;292(12):4833-4846. doi: 10.1074/jbc.M117.777409. Epub 2017 Feb 8.

PMID:
28184004
20.

Primary Sclerosing Cholangitis.

Lazaridis KN, LaRusso NF.

N Engl J Med. 2016 Dec 22;375(25):2501-2502. doi: 10.1056/NEJMc1613273. No abstract available.

21.

Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease.

Kittanamongkolchai W, El-Zoghby ZM, Eileen Hay J, Wiesner RH, Kamath PS, LaRusso NF, Watt KD, Cramer CH, Leung N.

Hepatol Int. 2017 Jul;11(4):384-389. doi: 10.1007/s12072-016-9775-9. Epub 2016 Dec 8.

PMID:
27933591
22.

Extracellular vesicles in liver pathobiology: Small particles with big impact.

Hirsova P, Ibrahim SH, Verma VK, Morton LA, Shah VH, LaRusso NF, Gores GJ, Malhi H.

Hepatology. 2016 Dec;64(6):2219-2233. doi: 10.1002/hep.28814. Epub 2016 Oct 20. Review.

23.

Primary Sclerosing Cholangitis.

Lazaridis KN, LaRusso NF.

N Engl J Med. 2016 Sep 22;375(12):1161-70. doi: 10.1056/NEJMra1506330. Review. No abstract available.

24.

Polycystic Liver Disease: The Benefits of Targeting cAMP.

Larusso NF, Masyuk TV, Hogan MC.

Clin Gastroenterol Hepatol. 2016 Jul;14(7):1031-4. doi: 10.1016/j.cgh.2016.03.008. Epub 2016 Mar 10. No abstract available.

25.

An Octogenarian With Acute Epigastric Pain: More Than Meets the Eye.

Lynn A, Tabibian JH, LaRusso NF.

Gastroenterology. 2016 Feb;150(2):e5-6. doi: 10.1053/j.gastro.2015.06.052. Epub 2015 Dec 23. No abstract available.

PMID:
26724265
26.

Performance of magnetic resonance elastography in primary sclerosing cholangitis.

Eaton JE, Dzyubak B, Venkatesh SK, Smyrk TC, Gores GJ, Ehman RL, LaRusso NF, Gossard AA, Lazaridis KN.

J Gastroenterol Hepatol. 2016 Jun;31(6):1184-90. doi: 10.1111/jgh.13263.

27.

Hail to the chief-Keith Lindor, our new AASLD president.

Shah VH, Gores GJ, LaRusso NF.

Hepatology. 2016 Feb;63(2):357-9. doi: 10.1002/hep.28342. Epub 2015 Dec 18. No abstract available.

PMID:
26566704
28.

The enteric microbiome in hepatobiliary health and disease.

Tabibian JH, Varghese C, LaRusso NF, O'Hara SP.

Liver Int. 2016 Apr;36(4):480-7. doi: 10.1111/liv.13009. Epub 2015 Dec 12. Review.

29.

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.

Hogan MC, Masyuk T, Bergstralh E, Li B, Kremers WK, Vaughan LE, Ihrke A, Severson AL, Irazabal MV, Glockner J, LaRusso NF, Torres VE.

Mayo Clin Proc. 2015 Aug;90(8):1030-7. doi: 10.1016/j.mayocp.2015.05.011. Epub 2015 Jul 9.

30.

TGR5 in the Cholangiociliopathies.

Masyuk TV, Masyuk AI, LaRusso NF.

Dig Dis. 2015;33(3):420-5. doi: 10.1159/000371696. Epub 2015 May 27.

31.

Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.

Tabibian JH, O'Hara SP, Trussoni CE, Tietz PS, Splinter PL, Mounajjed T, Hagey LR, LaRusso NF.

Hepatology. 2016 Jan;63(1):185-96. doi: 10.1002/hep.27927. Epub 2015 Aug 10.

32.

Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Munoz-Garrido P, Marin JJ, Perugorria MJ, Urribarri AD, Erice O, Sáez E, Úriz M, Sarvide S, Portu A, Concepcion AR, Romero MR, Monte MJ, Santos-Laso Á, Hijona E, Jimenez-Agüero R, Marzioni M, Beuers U, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Drenth JP, Banales JM.

J Hepatol. 2015 Oct;63(4):952-61. doi: 10.1016/j.jhep.2015.05.023. Epub 2015 Jun 1.

33.

The Cholangiopathies.

Lazaridis KN, LaRusso NF.

Mayo Clin Proc. 2015 Jun;90(6):791-800. doi: 10.1016/j.mayocp.2015.03.017. Epub 2015 May 6. Review.

34.

Therapeutic Targets in Polycystic Liver Disease.

Masyuk TV, Masyuk AI, LaRusso NF.

Curr Drug Targets. 2017;18(8):950-957. doi: 10.2174/1389450116666150427161743.

35.

The Achilles' heel of senescent cells: from transcriptome to senolytic drugs.

Zhu Y, Tchkonia T, Pirtskhalava T, Gower AC, Ding H, Giorgadze N, Palmer AK, Ikeno Y, Hubbard GB, Lenburg M, O'Hara SP, LaRusso NF, Miller JD, Roos CM, Verzosa GC, LeBrasseur NK, Wren JD, Farr JN, Khosla S, Stout MB, McGowan SJ, Fuhrmann-Stroissnigg H, Gurkar AU, Zhao J, Colangelo D, Dorronsoro A, Ling YY, Barghouthy AS, Navarro DC, Sano T, Robbins PD, Niedernhofer LJ, Kirkland JL.

Aging Cell. 2015 Aug;14(4):644-58. doi: 10.1111/acel.12344. Epub 2015 Apr 22.

36.

Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma.

Gradilone SA, Pisarello MJL, LaRusso NF.

Curr Drug Targets. 2017;18(8):958-963. doi: 10.2174/1389450116666150223162737.

37.

MicroRNAs and benign biliary tract diseases.

Gradilone SA, O'Hara SP, Masyuk TV, Pisarello MJ, LaRusso NF.

Semin Liver Dis. 2015 Feb;35(1):26-35. doi: 10.1055/s-0034-1397346. Epub 2015 Jan 29. Review.

38.

Polycystic liver diseases: advanced insights into the molecular mechanisms.

Perugorria MJ, Masyuk TV, Marin JJ, Marzioni M, Bujanda L, LaRusso NF, Banales JM.

Nat Rev Gastroenterol Hepatol. 2014 Dec;11(12):750-61. doi: 10.1038/nrgastro.2014.155. Epub 2014 Sep 30. Review.

39.

MicroRNAs in Cholangiopathies.

O'Hara SP, Gradilone SA, Masyuk TV, Tabibian JH, LaRusso NF.

Curr Pathobiol Rep. 2014 Sep 1;2(3):133-142.

40.

Calcium signaling in cilia and ciliary-mediated intracellular calcium signaling: are they independent or coordinated molecular events?

Masyuk AI, Gradilone SA, LaRusso NF.

Hepatology. 2014 Nov;60(5):1783-5. doi: 10.1002/hep.27331. Epub 2014 Oct 2. No abstract available.

41.

Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis.

Tabibian JH, Trussoni CE, O'Hara SP, Splinter PL, Heimbach JK, LaRusso NF.

Lab Invest. 2014 Oct;94(10):1126-33. doi: 10.1038/labinvest.2014.94. Epub 2014 Jul 21.

42.

Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.

Urribarri AD, Munoz-Garrido P, Perugorria MJ, Erice O, Merino-Azpitarte M, Arbelaiz A, Lozano E, Hijona E, Jiménez-Agüero R, Fernandez-Barrena MG, Jimeno JP, Marzioni M, Marin JJ, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Banales JM.

Gut. 2014 Oct;63(10):1658-67. doi: 10.1136/gutjnl-2013-305281. Epub 2014 Jan 16.

43.

HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.

Gradilone SA, Habringer S, Masyuk TV, Howard BN, Masyuk AI, Larusso NF.

Am J Pathol. 2014 Mar;184(3):600-8. doi: 10.1016/j.ajpath.2013.11.027. Epub 2014 Jan 13.

44.

Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis.

Tabibian JH, O'Hara SP, Splinter PL, Trussoni CE, LaRusso NF.

Hepatology. 2014 Jun;59(6):2263-75. doi: 10.1002/hep.26993. Epub 2014 Apr 25.

45.

Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.

Masyuk TV, Lee SO, Radtke BN, Stroope AJ, Huang B, Banales JM, Masyuk AI, Splinter PL, Gradilone SA, Gajdos GB, LaRusso NF.

Am J Pathol. 2014 Jan;184(1):110-21. doi: 10.1016/j.ajpath.2013.09.021. Epub 2013 Nov 7.

46.

Role for Krüppel-like transcription factor 11 in mesenchymal cell function and fibrosis.

Mathison A, Grzenda A, Lomberk G, Velez G, Buttar N, Tietz P, Hendrickson H, Liebl A, Xiong YY, Gores G, Fernandez-Zapico M, Larusso NF, Faubion W, Shah VH, Urrutia R.

PLoS One. 2013 Sep 17;8(9):e75311. doi: 10.1371/journal.pone.0075311. eCollection 2013.

47.

Gastroenterology's editors-in-chief: historical and personal perspectives of their editorships.

Fordtran JS, Goyal RK, Feldman M, Soll AH, Trier JS, Ockner RK, Larusso NF, Podolsky DK, Brenner DA, Rustgi AK, Omary MB.

Gastroenterology. 2013 Jul;145(1):16-31. doi: 10.1053/j.gastro.2013.05.019.

PMID:
23806784
48.

Physiology of cholangiocytes.

Tabibian JH, Masyuk AI, Masyuk TV, O'Hara SP, LaRusso NF.

Compr Physiol. 2013 Jan;3(1):541-65. doi: 10.1002/cphy.c120019. Review.

49.

The zebrafish as a model to study polycystic liver disease.

Tietz Bogert PS, Huang BQ, Gradilone SA, Masyuk TV, Moulder GL, Ekker SC, Larusso NF.

Zebrafish. 2013 Jun;10(2):211-7. doi: 10.1089/zeb.2012.0825. Epub 2013 May 13.

50.

Release of luminal exosomes contributes to TLR4-mediated epithelial antimicrobial defense.

Hu G, Gong AY, Roth AL, Huang BQ, Ward HD, Zhu G, Larusso NF, Hanson ND, Chen XM.

PLoS Pathog. 2013;9(4):e1003261. doi: 10.1371/journal.ppat.1003261. Epub 2013 Apr 4.

Supplemental Content

Loading ...
Support Center